Description

Rybelsus 3mg contains Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the body’s natural incretin hormones. It helps regulate blood glucose by:

Increasing insulin secretion in response to meals

Reducing glucagon release, which lowers liver glucose production

Slowing gastric emptying, promoting satiety and weight control

Rybelsus 3mg is the first oral GLP-1 receptor agonist, offering an alternative to injectable diabetes therapies. It is indicated for adults with type 2 diabetes to improve glycemic control, often alongside diet and exercise.

Usage Instructions

Take Rybelsus 3mg once daily, preferably in the morning on an empty stomach.

Swallow the tablet whole with a sip of water (not more than 120 mL).

Do not chew or crush the tablet.

Wait at least 30 minutes before eating, drinking, or taking other medications.

Follow your doctor’s instructions for dose escalation if prescribed.

Medicinal Advantages

Lowers HbA1c levels effectively

Supports weight loss in adults with type 2 diabetes

May reduce risk of cardiovascular events in high-risk patients

Convenient oral administration improves treatment adherence

Clinically proven in multiple studies for efficacy and safety

 

Side Effects

Common:

Nausea, vomiting, diarrhea, or constipation

Indigestion or decreased appetite

Mild headache or fatigue

Serious but rare:

Pancreatitis (severe abdominal pain)

Allergic reactions (rash, swelling, breathing difficulty)

Changes in kidney function

Note: Report persistent or severe side effects to a healthcare professional immediately.